Who is on it, and how far along Every drug ChEMBL records acting on IL2RA, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Antibody 2 Protein or peptide 2 Approved4 Aldesleukin Aldesleukin SponsorNovartis Pharmaceuticals ModalityProtein or peptide ActionAgonist Open trials64 Basiliximab Basiliximab SponsorNovartis Pharmaceuticals ModalityAntibody ActionInhibitor Open trials13 Denileukin diftitox Denileukin diftitox SponsorBeijing VDJBio Co., LTD. ModalityProtein or peptide ActionBinding agent Open trials4 Daclizumab Daclizumab SponsorBiogen ModalityAntibody ActionInhibitor Open trials2
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative Colitis Aldesleukin, Denileukin diftitox Phase 1 Recruiting Beijing VDJBio Co., LTD. Nov 12, 2026 Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Aldesleukin Phase 2 Not yet recruiting Beth Israel Deaconess Medical Center Nov 9, 2026 A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Aldesleukin Phase 2 Recruiting Iovance Biotherapeutics, Inc. Aug 3, 2026 Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT Daclizumab Phase 3 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Jul 8, 2026 A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma Aldesleukin Phase 1 / Phase 2 Recruiting AstraZeneca Jul 2, 2026 A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma Aldesleukin Phase 2 Not yet recruiting East Metropolitan Health Service, Australia Jun 16, 2026 Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease Aldesleukin Phase 1 / Phase 2 Recruiting The Methodist Hospital Research Institute Jun 16, 2026 Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin Phase 2 Not yet recruiting Joal Beane Jun 15, 2026 Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells Aldesleukin Not applicable Recruiting Cambridge University Hospitals NHS Foundation Trust May 28, 2026 Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Basiliximab Phase 2 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology May 7, 2026 Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease Basiliximab Phase 1 Recruiting Royan Institute May 7, 2026 Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML Basiliximab — Not yet recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology May 7, 2026 Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients Basiliximab Phase 4 Active, not recruiting University of Guadalajara Feb 24, 2026 Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL Basiliximab Phase 2 / Phase 3 Recruiting Shanxi Bethune Hospital Jul 10, 2025 HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata Denileukin diftitox Phase 1 Recruiting HCW Biologics Jul 3, 2025 A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel Denileukin diftitox Phase 1 / Phase 2 Recruiting Iovance Biotherapeutics, Inc. Apr 23, 2025 Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases Basiliximab Phase 2 Not yet recruiting Anhui Provincial Hospital Jun 28, 2024 1 vs 7 RATG Infusions in Renal Transplantation Basiliximab — Active, not recruiting Mario Negri Institute for Pharmacological Research Apr 18, 2024 Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Basiliximab Phase 3 Recruiting University Hospital, Tours May 23, 2022 T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Denileukin diftitox Phase 1 / Phase 2 Active, not recruiting Alexander B Olawaiye, MD Jan 20, 2022 Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen Daclizumab Phase 1 Active, not recruiting City of Hope Medical Center Jun 27, 2008
Show all 21Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364167 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets